Prescribing Practices of Rural Physicians Waivered to Prescribe Buprenorphine
- PMID: 29779544
- DOI: 10.1016/j.amepre.2018.02.006
Prescribing Practices of Rural Physicians Waivered to Prescribe Buprenorphine
Abstract
Introduction: Opioid use disorder is a serious public health burden, especially throughout rural America. Although efforts have been made to increase the availability of buprenorphine (an office-based medication-assisted treatment), more than 60% of rural counties in the U.S. lack a physician with a Drug Enforcement Administration waiver to prescribe it.
Methods: This study surveyed all rural physicians with a Drug Enforcement Administration waiver in 2016 to prescribe buprenorphine for opioid use disorder in the U.S. and asked about physician's demographics, prescribing practices, and barriers to prescribing buprenorphine for treatment of opioid use disorder.
Results: Although 89.4% of physicians reported having prescribed buprenorphine for opioid use disorder, only 56.2% were currently accepting new patients for treatment. Physicians with a 30-patient waiver were treating, on average, 8.8 patients, but 53% were not treating any patients. Those with a 100-patient waiver were treating, on average, 56.9 patients. Significant practice variations were found throughout the U.S. by Census Division; more physicians in the Pacific Census Division accepted their own patients for treatment with buprenorphine whereas more physicians in the New England Census Divisions accepted patients of other clinicians in their practice. Although most physicians accepted private insurance, significantly fewer physicians in the East South Central and West South Central Census Divisions accepted Medicaid.
Conclusions: These findings suggest that without incorporating information about whether or not physicians are accepting new patients, how many patients are being treated, and which patients and reimbursements are accepted, estimating the supply of buprenorphine treatment services using the Drug Enforcement Administration waivered physicians list will overestimate treatment availability.
Supplement information: This article is part of a supplement entitled The Behavioral Health Workforce: Planning, Practice, and Preparation, which is sponsored by the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration of the U.S. Department of Health and Human Services.
Copyright © 2018 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder.Ann Fam Med. 2017 Jul;15(4):359-362. doi: 10.1370/afm.2099. Ann Fam Med. 2017. PMID: 28694273 Free PMC article.
-
Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians.J Rural Health. 2019 Jan;35(1):113-121. doi: 10.1111/jrh.12328. Epub 2018 Oct 19. J Rural Health. 2019. PMID: 30339720
-
Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.Addiction. 2019 Mar;114(3):471-482. doi: 10.1111/add.14436. Epub 2018 Oct 15. Addiction. 2019. PMID: 30194876
-
Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.Rural Remote Health. 2015;15:3019. Epub 2015 Feb 4. Rural Remote Health. 2015. PMID: 25651434 Review.
-
Buprenorphine X-waiver exemption - beyond the basics for the obstetrical provider.Am J Obstet Gynecol MFM. 2021 Nov;3(6):100451. doi: 10.1016/j.ajogmf.2021.100451. Epub 2021 Jul 25. Am J Obstet Gynecol MFM. 2021. PMID: 34320429 Review.
Cited by
-
Harm Reduction Services to Prevent and Treat Infectious Diseases in People Who Use Drugs.Infect Dis Clin North Am. 2020 Sep;34(3):605-620. doi: 10.1016/j.idc.2020.06.013. Infect Dis Clin North Am. 2020. PMID: 32782104 Free PMC article. Review.
-
Prescribers' satisfaction with delivering medications for opioid use disorder.Subst Abuse Treat Prev Policy. 2021 Oct 18;16(1):78. doi: 10.1186/s13011-021-00413-7. Subst Abuse Treat Prev Policy. 2021. PMID: 34663379 Free PMC article. Clinical Trial.
-
Routes of non-traditional entry into buprenorphine treatment programs.Subst Abuse Treat Prev Policy. 2020 Jan 20;15(1):6. doi: 10.1186/s13011-020-0252-z. Subst Abuse Treat Prev Policy. 2020. PMID: 31959194 Free PMC article.
-
Strategies to recruit rural primary care providers to implement a medication for opioid use disorder (MOUD) focused integrated care model.Implement Res Pract. 2023 Feb 19;4:26334895231152808. doi: 10.1177/26334895231152808. eCollection 2023 Jan-Dec. Implement Res Pract. 2023. PMID: 37091535 Free PMC article.
-
Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System.NAM Perspect. 2020 Apr 27;2020:10.31478/202004b. doi: 10.31478/202004b. eCollection 2020. NAM Perspect. 2020. PMID: 35291732 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical